Compare Crispr Therapeutics AG (CRSP) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs MasTec Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while MasTec Inc trades at $212.65 (market cap $17.40B). The key difference: MasTec Inc is far larger — about 3.6× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and MasTec Inc for 23 Days on average.
| CRSP | MTZ | |
|---|---|---|
Market Cap | $4.88B | $17.40B |
Volume | 2,861,747 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $73.97 | $437.51 |
52-Week Low | $44.34 | $190.08 |
Typical Hold Time | 77 Days | 23 Days |
Enterprise Value | $3.30B | $20.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
MasTec (MTZ) trades at $216.66, down 3.0% on the day, with technical indicators showing bearish momentum as the stock trades below key moving averages. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust revenue growth projections for 2026. Analyst sentiment remains overwhelmingly positive with 89% buy ratings and a consensus price target of $408.58, representing significant upside potential from current levels.
MTZ presents a compelling growth story with record $21.4B backlog and exposure to infrastructure investment cycles, though premium valuation metrics and recent cash flow weakness warrant caution. The stock's current discount to analyst targets offers opportunity, but execution risks in communications segment and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
